A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)

Phase 2RecruitingNCT06185764

Vertex Pharmaceuticals Incorporated36 enrolled

Overview

The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of VX-670 at different single and multiple doses in participants with DM1.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

Conditions

Myotonic Dystrophy Type 1 (DM1)

Interventions

VX-670DRUG

Solution for intravenous administration.

PlaceboDRUG

Solution for intravenous administration.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 64 Years

Medical Language ↔ Plain English

Key Inclusion Criteria: \- Documented clinical diagnosis of DM1 with age of onset greater than (\>) 1 year of age and documented positive genetic test for DM1 in the subject with cytosine thymine guanine (CTG) repeat of at least 100 Key Exclusion Criteria: \- History of any illness or any clinical condition as pre-specified in the protocol Other protocol defined Inclusion/Exclusion criteria may apply.

Locations (26)

Outcomes

Primary Outcomes

Parts A and B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs)

Time frame: Part A: From Baseline up to Day 42; Part B: From Baseline and up to Day 168

Secondary Outcomes

Part A: Maximum Observed Concentration (Cmax) of VX-670 and its Active Component in Plasma

Time frame: From Day 1 up to Day 42

Part A: Area Under the Concentration Versus Time Curve (AUC) of VX-670 and its Active Component in Plasma

Time frame: From Day 1 up to Day 42

Part B: Maximum Observed Concentration (Cmax) of VX-670 and its Active Component in Plasma After Each Dose

Time frame: From Day 1 up to Day 168

Part B: Area Under the Concentration Versus Time Curve (AUC) of VX-670 and its Active Component in Plasma After Each Dose

Time frame: From Day 1 up to Day 168

Part B: Concentration of VX-670 and its Active Component in Muscle

Time frame: Baseline and at Day 15

Part B: Change in Splicing Index in Muscle Biopsy

Time frame: Baseline and at Day 15

Central Contacts

Medical Information

CONTACT

617-341-6777 medicalinfo@vrtx.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Stanford Neuromuscular Research

San Carlos, California, United States

RECRUITING

University of Florida Clinical Research Center

Gainesville, Florida, United States

RECRUITING

University of Kansas Medical Center

Fairway, Kansas, United States

RECRUITING

Boston Children's Hospital

Boston, Massachusetts, United States

RECRUITING

Washington University School of Medicine / St. Louis Children's Hospital

St Louis, Missouri, United States

RECRUITING

Wake Forest Baptist Health

Winston-Salem, North Carolina, United States

RECRUITING

University of Pennsylvania

Philadelphia, Pennsylvania, United States

RECRUITING

Virginia Commonwealth University (Sanger Hall)

Richmond, Virginia, United States

RECRUITING

Wesley Research Institute

Auchenflower, Australia

RECRUITING

Neuroscience Clinical Trials Unit, Alfred Brain

Melbourne, Australia

RECRUITING

...and 16 more locations